NCT01086020.

Methods	Randomised open‐label parallel group study, 2 years follow‐up
Participants	Inclusion Criteria: age 18 to 75 years; willing to receive the coronary angiography and potential PCI therapy Exclusion Criteria: patients was treated by statins before randomisation; patient with ≤ 20% and ≥ 70% coronary narrowing and target lesion; ST elevation myocardial infarction less than 7 days; without informed consent; abnormal liver function before randomisation, (AST, ALT ≥ ULN); active hepatitis or muscular disease; impaired renal function with serum creatinine level > 3 mg/dL; impaired left ventricular function with LVEF > 30%; participate in other studies.
Interventions	Atorvastatin 10 mg/day versus atorvastatin 5 mg/day plus ezetimibe 5 mg/day
Outcomes	Primary endpoint: the change of coronary artery plaque volume measured by intravascular ultrasound (IVUS) at one year after randomisation. Secondary endpoint: the composite of adverse cardiac events (MACE), including cardiac death, non‐fatal infarction and target vessel revascularisation at two years after randomisation.
Notes	Study Start Date: January 2010 Recruitment Status: unknown Last Update Posted: April 4, 2011 Location: China Contact information: Ruiyan Zhang, MD; zhangruiyan@263.net Contacted trialists to ask about status and anticipated completion date, but no response.